Causes, Symptoms, Diagnosis, and Consequences of GERD

August 1, 2011

Article

Two physicians discuss the causes, symptoms, diagnosis, and consequences of gastroesophageal reflux disease (GERD).

In this video, Daniel C. DeMarco, MD, director of endoscopy at the Baylor University Medical Center in Dallas, and Rajeev Jain, MD, a gastroenterologist based in Dallas, discuss the causes, symptoms, diagnosis, and consequences of GERD.

Recent Videos

Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates

Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center

Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group

Carl C. Awh, MD: | Image Credit:

Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest

Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas

Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital

Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates

Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn

Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina

Related Content

Gilaad Kaplan, MD, MPH | Credit: University of Calgary

Risankizumab Induction, Maintenance Therapy Improves Clinical Remission Rates in UC

Abigail Brooks, MA

Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Abigail Brooks, MA

Vonoprazan (Voquezna) Receives FDA Approval for Heartburn Associated with Non-Erosive GERD

Abigail Brooks, MA

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

April 17th 2024

David Levinthal, MD, PhD | Credit: University of Pittsburgh

Cyclic Vomiting Syndrome Clinical Practice Update Guides Diagnosis, Management

Abigail Brooks, MA

Mirna Chehade, MD, MPH | Credit: Mount Sinai

Mirna Chehade, MD, MPH: “Exciting” Phase 3 Data for Dupilumab in Pediatric Eosinophilic Esophagitis

Abigail Brooks, MA

Related Content

Gilaad Kaplan, MD, MPH | Credit: University of Calgary

Risankizumab Induction, Maintenance Therapy Improves Clinical Remission Rates in UC

Abigail Brooks, MA

Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Abigail Brooks, MA

Vonoprazan (Voquezna) Receives FDA Approval for Heartburn Associated with Non-Erosive GERD

Abigail Brooks, MA

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

April 17th 2024

David Levinthal, MD, PhD | Credit: University of Pittsburgh

Cyclic Vomiting Syndrome Clinical Practice Update Guides Diagnosis, Management

Abigail Brooks, MA

Mirna Chehade, MD, MPH | Credit: Mount Sinai

Mirna Chehade, MD, MPH: “Exciting” Phase 3 Data for Dupilumab in Pediatric Eosinophilic Esophagitis

Abigail Brooks, MA

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.